h epatitis viral infection and non-alcoholic fatty liver disease (nafld) : an update
DESCRIPTION
H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE. L.A. Lesmana Department of Medicine, University of Indonesia , Jakarta. NALFD – AAS LD definition 2012 . Evidence of hepatic steatosis, by imaging or by histology, - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/1.jpg)
L.A. LesmanaDepartment of Medicine, University of Indonesia , Jakarta
HEPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE
(NAFLD) : AN UPDATE
![Page 2: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/2.jpg)
NALFD – AASLD definition 2012 Evidence of hepatic steatosis, by imaging or
by histology,No causes for secondary hepatic fat
accumulation
Chalasani N, et al. Gastroenterology 2012;142:1592-1609.
![Page 3: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/3.jpg)
Prevalence of NAFLD in the Asia-Pacific region
Country Percentage of NAFLD
Japan 9 – 30%China 5 – 18%Korea 18 %India 5 – 28%Indonesia 30%Malaysia 17 %Singapore 5%
Amarapurkar. Asia Pacific Working Party on NAFLD 2006
![Page 4: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/4.jpg)
Insulin Resistance and Hepatitis
Hep B Hep C Cleared Hep C
0
10
20
30
40
50
60
IR
%
p<0.005 p<0.005
Imazeki et al. Liver Int 2008:355-62
![Page 5: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/5.jpg)
Chronic Hepatitis B (CHB) and NAFLDCurrent Evidence
![Page 6: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/6.jpg)
Prevalence of steatosis in CHBStudies Year Country Number of
casessPrevalence of steatosis (%)
Altlparmak et al.
2005 Turkey 164 39
Gordon et al. 2005 Australia 17 76Thomopulos et al.
2006 Greece 233 18
Bondini et al 2007 USA 153 32Peng et al 2008 China 153 27Rastogi et al 2011 India 350 34Lesmana et al 2012 Indonesi
a174 30
Thomopoulos KC, et al. Eur J Gastroenterol Hepatol 2006;18:233-7Altlparmak E, et al. World J Gastroenterol 2005;11:3056-9.Gordon A, et al. J Hepatol 2005;43:38-44.Peng D, et al. J Gastroenterol Hepatol 2008;23:1082-8.
Bondini S, et al. Liver Int 2007;27:607-11.Rastogi A. et al. Indian J Pathol Microbiol 2011;54:454-9.Lesmana LA, et al. Acta Med Indones 2012;44:35-9.
![Page 7: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/7.jpg)
Factors associated with FL in CHBFatty Liver (-)
(n=100)Fatty Liver (+)
(n=64)p-value
Mean age (years) 33.2 + 11.70 37.9 + 10.09 0.006Mean BMI (kg/m2) 25.3 + 3.93 27.8 + 3.70 0.000Male sex, n(%) 60 (53.1) 53 (46.9) 0.008Mean AST (U/L) 76.5 + 56.14 70.0 + 54.61 0.469Mean ALT (U/L) 131.6 + 109.39 113.5 + 68.19 0.686Mean cholesterol (mg/dL) 162.2 + 38.8) 184.9 + 34.5 0.000Mean triglyceride (mg/dL) 102.5 + 44.66 133.7 + 65.96 0.004HBeAg positive, n(%) 42 (41.4) 17 (27.0) 0.059Mean viral load (pg/mL) 1,628.24 781.55 0.067Fibrosis stage 2-3, n(%) 20 (20) 11 (17.2) 0.754HAI 9-17, n(%) 36 (36) 23 (35.9) 0.772
Altlrmak E , et al. World J Gastroenterol 2005;11:3056-9.
![Page 8: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/8.jpg)
Insulin Resistance in CHBHOMA-IR
<1.64(n=35)
HOMA-IR > 1.64
(n=34)
p-value
Mean BMI (kg/m2) 21.8 + 3.7 24.0 + 4.4 0.029
Mean waist circumference (cm)
80.1 + 8.6 85.1 + 10.2 0.089
Median triglyceride (mg/dL) 90.0 110.0 0.016
Median fasting insulin (μU/mL)
5.0 11.7 <0.001
Fasting glucose (mg/dL) 85 53 <0.001
Fibrosis F2-F4, n(%) 21 (60.0) 15 (54.2) 0.232
HAI >6, n(%) 11 (31.4) 10 (29.4) 0.717
Steatosis grade 1-2 20 (57.2) 21 (61.8) 0.873
Median HBV-DNA (log copies/mL)
5.14 6.2 0.324
HBeAg positive, n(%) 13 (37.1) 13 (38.2) 1.000Kumar M, et al. Am J Gastroenterol 2009;104:76-82.
![Page 9: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/9.jpg)
Demographic FactorsVariable Steatosis (+)
(n=118)Steatosis (-)
(n=232)p value
Mean age 35.5 + 10.5 27.9 + 14.0 <0.001Male : Female 108 : 10 192 : 40 0.045
Rastogi A. et al. Indian J Pathol Microbiol 2011;54:454-9.
Variable Steatosis (+)
(n=52)
Steatosis (-)
(n=122)
p value OR(95%CI)
Mean age 42.6 + 10.5
40.0 + 11.2 0.150 -
Male : Female (%)
73.1 : 26.9 49.2 : 50.8 0.004 2.81 (1,38-5,69)
Medistra Hospital. Unpublished data 2007-2009
![Page 10: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/10.jpg)
Biochemical and Viral FactorsVariable Steatosis
(+)(n=118)
Steatosis (-)(n=232)
p value
Median ALT (U/mL) 62 68 0.620HBeAg positive (%) 48.8 57.2 0.106Median DNA (copies/mL)
69 x 104 750 x 104 0.025
HBV genotypes (n=80):ABCDA+CA+DA+C+D
12.6%00
81.2%3.1%3.1%
0
14.5%2.1%2.1%64.6%2.1%12.5%2.1%
0.567
Rastogi A. et al. Indian J Pathol Microbiol 2011;54:454-9.
![Page 11: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/11.jpg)
Metabolic Parameters Variable Steatosis
(+)(n=118)
Steatosis (-)(n=232)
p value
Mean BMI (kg/m2) 25.2 + 4.8 20.4 + 3.5 <0.01Mean FBS (mg/dL) 94.1 + 19.6 86.9 + 13.9 0.091Mean TG (mg/dL) 138.8 + 62.1 88.0 + 27.9 0.002Mean cholesterol (mg/dL)
171.8 + 43.5 139.3 + 37.6 0.017
Mean insulin (IU/L) 13.0 + 9.1 9.1 + 6.0 0.027Median HOMA-IR 2.7 (0.96-
11.75)1.9 (0.19-6.7) 0.048
Rastogi A. et al. Indian J Pathol Microbiol 2011;54:454-9.
BMI: body mass index; FBS: fasting blood sugar; TG: triglycerides;HOMA-IR: Homeostatic Model of Assessment – Insulin Resistance
![Page 12: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/12.jpg)
Histological Features
Rastogi A. et al. Indian J Pathol Microbiol 2011;54:454-9.
Variable Steatosis (+)(n=118)
Steatosis (-)(n=232)
p value
Mean HAI score 4.8 + 2.6 4.5 + 2.9 0.286Mean fibrosis score 1.7 + 1.1 1.5 + 1.1 0.170
HAI: histological activity index
![Page 13: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/13.jpg)
Data in Medistra HospitalVariable Steatosis
(+)(n=118)
Steatosis (-)(n=232)
p value
Mean BMI (kg/m2) 25.1 + 3.7 22.7 + 3.3 <0.001Waist circumference (cm)
88.3 + 11.0 79.0 + 10.1 <0.001
Mean ALT (U/L) 49.8 + 26.7 71.7 + 102.9 0.132Log HBV-DNA (copies/mL)
5.92 + 1.99 6.07 + 2.08 0.675
Liver stiffness (kPa) 8.3 + 6.3 9.5 + 10.2 0.468HBeAg-positive (%) 42.3 45.1 0.736Genotype C (%) 32.4 19.8 0.138
Lesmana LA, et al. Acta Med Indones 2012;44:35-9.
![Page 14: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/14.jpg)
Histological FeaturesFibrosis stage Inflammatory grade
F0-F1 F2-F40
102030405060708090
100
FL(+) FL(-)
% o
f cas
es
A0-A1 A2-A30
20
40
60
80
100
FL(+) (FL-)
% o
f cas
es
p = 0.849 p = 0.624
Lesmana LA, et al. Acta Med Indones 2012;44:35-9.
![Page 15: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/15.jpg)
Predictors of Steatosis in CHBCountr
yN Steatos
isPredictors
Altlparmak, et al (2005)
Turkey 164
39% Older age, BMI, high cholesterol and triglyceride
Gordon, et al (2005) Australia
17 76% Waist circumference, FPG, C-peptide
Thomopoulos, et al (2006)
Greece 233
18% FPG, BMI> 25 kg/m2
Bondini, et al (2007) USA 64 19% Obesity, waist circumference, hypergension, dyslipidemia, older age
Cindoruk, et al (2007) Turkey 140
34% BMI, total cholesterol, hypertriglyceridemia
Peng, et al (2008) China 153
27% BMI, Age ALT
Rastogi, et al (2011) India 350
34% Triglyceride
Lesmana, et al (2012) Indonesia
174
30% Waist circumference
![Page 16: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/16.jpg)
Fatty Liver vs. SVR Rates
Cindoruk M, et al. J Clin Gastroenterol 2007;41:513-7.
HBeAg (-) HBeAg (+)0%
10%
20%
30%
40%36.20% 39.60%
31.50% 33.30%
With steatosis Without steatosis
FL did not affect IFN-based treatment outcomes (p > 0.005)
![Page 17: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/17.jpg)
ALT
HBeAg+
HBV DNA
Immune Escape/Reactivation
Inactive Carrier Status
HBeAg – Chronic HBV
HBeAg +Chronic Hepatitis B
Immune Tolerant
ImmuneControl
Immune Clearance
Immune control – treatment not required
Immune control – inactive disease
HBeAg–
![Page 18: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/18.jpg)
Summary: NAFLD in CHBNAFLD is commonly found in about one-third of
patients.NAFLD in CHB is strongly associated with
metabolic factors, e.g.: body mass index (BMI), obesity, insulin resistance, dyslipidemia.
NAFLD is not associated with liver fibrosis or histological activity index.
NAFLD may not affect treatment response.In patients with CHB and NAFLD with elevated ALT
in clinical practice is not easy to distinguish whether the high ALT is due to CHB or NAFLD.
![Page 19: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/19.jpg)
Chronic Hepatitis C (CHC) and NAFLDCurrent Evidence
![Page 20: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/20.jpg)
Risk factors of FL in Chronic Hep C
Parameter HCV (n=75) HCV+ FL (n=69)
p value
Obesity 25 52 <0.05Diabetes 8 21 <0.05Hypertension 14 25 <0.05Hypertriglyceridemia 15 33 <0.05Metabolic syndrome 28 63 <0.001
Fatty liver is associated with features of metabolic syndrome in patients
with chronic hepatitis C virus infection.
Sanyal AJ, et al. Am J Gastroenterol 2003;98:2064-71
![Page 21: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/21.jpg)
IR and Liver Fibrosis in CHC
F0-F1 F2-F40
102030405060708090
100
9
91
33
67
HOMA-R >2.5HOMA-R <2.5
% o
f cas
es
Taura N, et al. Am J Gastroenterol 2006;101:2752-9.
Insulin resistance is associated with more advanced fibrosis in patients with chronic hepatitis C virus infection
p = 0.002
![Page 22: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/22.jpg)
HCV GENOTYPE DISTRIBUTION
1a 1b 1c 2a 2e 2f 3a 3k05
101520253035404550
6.7
47.3
18.7
105.3
0.7 0.7
10.7
HCV genotype 1b is predominant in Indonesia
Utama A, et al. Liver Int 2010;30:1152-60.
Subjects: 68 chronic hepatitis, 48 cirrhosis, and 34 HCCMethod: core sequence analyses
%
![Page 23: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/23.jpg)
Relapse rate are higher in patients infected with HCV genotype 3 who have an RVR
RVR SVR Relapse0
102030405060708090
86.7 84.3
10.1
79.6 79.2
15.6
Genotype 2 (n=427)Genotype 3 (n=505)
Res
pond
ers
(%)
Shah SR, et al. Clin Gastroenterol Hepatol 2011;9:688-93.
RVR: rapid virologic response (HCV RNA <43 IU/mL at week-4 ) SVR: sustained virologic response (HCV RNA <15 IU/mL at week-48
p=0.001
![Page 24: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/24.jpg)
Steatosis is the strongest independent predictor of relapse in patients infected with HCV
genotype 3 who have an RVR
Shah SR, et al. Clin Gastroenterol Hepatol 2011;9:688-93.
OR: 3.0; 95%CI: 1,5-6.1; p=0.003 Steatosis vs. no steatosis
HCV RNA > vs. < 400.000 IU/mL
BMI > vs < 30 kg/m2
Age > vs <45 years
GGT > vs < ULN
OR: 2.5; 95%CI: 1,0-6.3; p=0.04
OR: 2.2; 95%CI: 1,0-4.8; p=0.04
OR: 2.2; 95%CI: 1,2-4.2; p=0.02
OR: 2.1; 95%CI: 1,1-4.1; p=0.03
-2 -1 0 1 2 3 4 5 6 7 8
![Page 25: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/25.jpg)
HCV infection and Metabolic Syndrome
There is no evidence for association between HCV infection and metabolic syndrome.
The 2 conditions occur together at a higher rate than would occur by chance, although HCV infection has been associated with type2 diabetes mellitus.
The serum lipid profile of patients with HCV infections is characterized by decreased level of cholesterol and sometimes triglycerides,in contrast to metabolic syndrome
Negro F. Gastroenterology 2012;142:1288-92
![Page 26: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/26.jpg)
HCV and Lipid Metabolism that may lead to steatosis of hepatocytes
Negro F. Gastroenterology 2012;142:1288-92.
![Page 27: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/27.jpg)
HCV might affect insulin signaling in hepatocytes contributing to Insulin Resistance
Negro F. Gastroenterology 2012;142:1288-92.
![Page 28: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/28.jpg)
Possible Clinical Outcomes Insulin resistance in CHC
have substantial impact on the morbidity and mortality :Accelerated progression
of liver fibrosis Increase type 2 diabetesReduced virological
response to antiviral therapy
Increase incidence of cardiovascular events need further study
Bugianesi E, et al. J Hepatol 2012;56(Suppl ):S56-S65
![Page 29: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/29.jpg)
Summary: NAFLD in CHCNAFLD is frequently found in CHCIts present is genotype specific, mostly
genotype 1 and 3Alcohol, central obesity, raised BMI are
associated with more activity and more severe fibrosis
Obesity reduces response to IFN-based treatment
NAFLD may increase relapse rate among previously rapid virologic responders
![Page 30: H EPATITIS VIRAL INFECTION and NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) : AN UPDATE](https://reader036.vdocument.in/reader036/viewer/2022070423/5681666a550346895dda0278/html5/thumbnails/30.jpg)
THANK YOU